logo

For the Inventor, By the Inventor

East Lyme, CT, United States of America

Meijia Yang

USPTO Granted Patents = 11

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 75(Granted Patents)


Company Filing History:

goldMedal11 out of 84 
 
Curagen Corporation
 patents

Years Active: 1999-2007

Loading Chart...
11 patents (USPTO):Explore Patents
1. 7253266 - Polypeptides of FGF-CX (2007-08-07),
2. 7056885 - Fibroblast growth factor and nucleic acids encoding same (2006-06-06),
3. 6916907 - Nucleic acids encoding osteoprotegern-like proteins and methods of using same (2005-07-12),
4. 6627405 - 53BP2 complexes (2003-09-30),
5. 6573364 - Isolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteins (2003-06-03),
6. 6521412 - HsReq*1 and hsReq*2proteins and use thereof to detect CDK2 (2003-02-18),
7. 6410239 - Identification and comparison of protein—protein interactions that occur in populations and identification of inhibitors of these interactors (2002-06-25),
8. 6372490 - Nucleic acid encoding the MDM interacting protein (2002-04-16),
9. 6057101 - Identification and comparison of protein-protein interactions that occur (2000-05-02),
10. 5986055 - CDK2 interactions (1999-11-16),
11. 5977311 - 53BP2 complexes (1999-11-02),

Title: The Innovative Contributions of Meijia Yang

Introduction

Meijia Yang is a prominent inventor based in East Lyme, CT (US). She has made significant contributions to the field of biotechnology, particularly in the development of polypeptides and their applications in medical science. With a total of 11 patents to her name, Yang's work has the potential to impact various pathological states and therapeutic methods.

Latest Patents

Among her latest inventions is the patent for Polypeptides of FGF-CX. This invention provides FGF-CX, a novel isolated polypeptide, along with a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide, or antibody. The invention also outlines methods for using the FGF-CX polypeptide, polynucleotide, and antibody in the detection and treatment of a broad range of pathological states. Another significant patent is for Fibroblast growth factor and nucleic acids encoding the same, which similarly provides FGF-CX polypeptides and polynucleotides, along with antibodies that bind to FGF-CX.

Career Highlights

Meijia Yang is currently associated with Curagen Corporation, where she continues to innovate and develop new technologies. Her work has been instrumental in advancing the understanding of fibroblast growth factors and their applications in medicine.

Collaborations

Yang has collaborated with notable colleagues, including Krishnan Nandabalan and Vincent Peter Schulz, to further her research and development efforts.

Conclusion

Meijia Yang's contributions to biotechnology through her innovative patents and collaborations highlight her role as a leading inventor in her field. Her work continues to pave the way for advancements in medical treatments and diagnostics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…